UT Southwestern, Harold C. Simmons Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 12 Trials 
7 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Landau, Heather
NCT02909036: Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

Active, not recruiting
1
46
US
Melphalan, Pegfilgrastim, Autologous Hematopoietic Progenitor Cell Transplant
Memorial Sloan Kettering Cancer Center, Spectrum Pharmaceuticals, Inc
Multiple Myeloma, Amyloidosis
09/25
09/25
NEXICART-2, NCT06097832: Study of NXC-201 CAR-T in Patients with Light Chain (AL) Amyloidosis

Recruiting
1
40
US
NXC-201 CAR-T, HBI0101 CAR-T
Nexcella Inc., Immix Biopharma, Inc.
Light Chain (AL) Amyloidosis
12/26
01/39
Tuchman, Sascha
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
NCT04009109: Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

Active, not recruiting
2
79
US
Lenalidomide, Revlimid, Ixazomib, Ninlaro, Daratumumab Injection, Darzalex, Dexamethasone, Ozurdex
Alliance Foundation Trials, LLC., Janssen Scientific Affairs, LLC, Celgene Corporation, Takeda
Myeloma, Multiple
10/25
07/26
NCT05145400: Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Recruiting
2
50
US
Isatuximab, Lenalidomide, REVLIMID, Dexamethasone
UNC Lineberger Comprehensive Cancer Center, Genzyme, a Sanofi Company
Multiple Myeloma, Cancer
03/26
03/31
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Hourglass Feb 2024 - Dec 2024 : Results from STOMP trial for RRMM and NDMM
Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
More
Recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
DREAMM 12, NCT04398745: A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

Recruiting
1
36
Europe, US, RoW
Belantamab mafodotin, GSK2857916
GlaxoSmithKline
Multiple Myeloma
02/25
02/25
Axelrod, Bayley
No trials found

Download Options